Hasnyálmirigyrák: az ESMO klinikai gyakorlati irányelve a diagnózishoz, kezeléshez, követéshez

T. Conroy (1,2), P. Pfeiffer (3), V. Vilgrain (4,5), A. Lamarca (6), T. Seufferlein (7), E. M. O’Reilly (8), T. Hackert (9), T. Golan (10), G. Prager (11), K. Haustermans (12), A. Vogel (13) & M. Ducreux (14), az ESMO Guidelines Committee részéről
(1) Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy
(2) APEMAC, équipe MICS, Université de Lorraine, Nancy, France
(3) Department of Oncology, Odense University Hospital, Odense, Denmark
(4) Centre de Recherche sur l’Inflammation U 1149, Université Paris Cité, Paris
(5) Department of Radiology, Beaujon Hospital, APHP Nord, Clichy, France
(6) Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
(7) Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany
(8) Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
(9) Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany
(10) Gastrointestinal Unit, Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
(11) Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
(12) Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
(13) Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
(14) Université Paris-Saclay, Gustave Roussy, Inserm Unité Dynamique des Cellules Tumorales, Villejuif, France